UBX Depositi SEC - Unity Biotechnology, Inc.- Relazione annuale, dichiarazione di delega, prospetto informativo

Statistiche di base

LEI	549300WDOM0RU3CUO763
CIK	1463361

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Unity Biotechnology, Inc.

SEC Filings (Chronological Order)

Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.

August 25, 2025	S-8 POS	As filed with the Securities and Exchange Commission on August 25, 2025 S-8 POS As filed with the Securities and Exchange Commission on August 25, 2025 Registration No.
August 25, 2025	S-8 POS	As filed with the Securities and Exchange Commission on August 25, 2025 S-8 POS As filed with the Securities and Exchange Commission on August 25, 2025 Registration No.
August 25, 2025	S-8 POS	As filed with the Securities and Exchange Commission on August 25, 2025 S-8 POS As filed with the Securities and Exchange Commission on August 25, 2025 Registration No.
August 25, 2025	S-8 POS	As filed with the Securities and Exchange Commission on August 25, 2025 S-8 POS As filed with the Securities and Exchange Commission on August 25, 2025 Registration No.
August 25, 2025	S-8 POS	As filed with the Securities and Exchange Commission on August 25, 2025 S-8 POS As filed with the Securities and Exchange Commission on August 25, 2025 Registration No.
August 25, 2025	S-8 POS	As filed with the Securities and Exchange Commission on August 25, 2025 S-8 POS As filed with the Securities and Exchange Commission on August 25, 2025 Registration No.
August 25, 2025	S-8 POS	As filed with the Securities and Exchange Commission on August 25, 2025 S-8 POS As filed with the Securities and Exchange Commission on August 25, 2025 Registration No.
August 25, 2025	S-8 POS	As filed with the Securities and Exchange Commission on August 25, 2025 S-8 POS As filed with the Securities and Exchange Commission on August 25, 2025 Registration No.
August 25, 2025	S-8 POS	As filed with the Securities and Exchange Commission on August 25, 2025 S-8 POS As filed with the Securities and Exchange Commission on August 25, 2025 Registration No.
August 25, 2025	S-8 POS	As filed with the Securities and Exchange Commission on August 25, 2025 S-8 POS As filed with the Securities and Exchange Commission on August 25, 2025 Registration No.
August 11, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (
August 1, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a
July 24, 2025	EX-3.1	UNITY BIOTECHNOLOGY, INC. CERTIFICATE OF DESIGNATION SERIES A PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware EX-3.1 Exhibit 3.1 UNITY BIOTECHNOLOGY, INC. CERTIFICATE OF DESIGNATION OF SERIES A PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Unity Biotechnology, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by the board of directors of the Corporation (the “B
July 24, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2025 DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2025 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction o
July 24, 2025	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2025 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorp
July 24, 2025	EX-10.1	PURCHASE AGREEMENT EX-10.1 Exhibit 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (this “Agreement”) is made as of July 22, 2025, by and between the purchaser listed on Exhibit A attached hereto (the “Purchaser”) and Unity Biotechnology, Inc., a Delaware corporation (the “Company”). RECITALS WHEREAS: The Company desires to sell to the Purchaser, and the Purchaser desires to purchase from the Company, one share of S
July 22, 2025	EX-10.1	PURCHASE AGREEMENT EX-10.1 Exhibit 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (this “Agreement”) is made as of July 22, 2025, by and between the purchaser listed on Exhibit A attached hereto (the “Purchaser”) and Unity Biotechnology, Inc., a Delaware corporation (the “Company”). RECITALS WHEREAS: The Company desires to sell to the Purchaser, and the Purchaser desires to purchase from the Company, one share of S
July 22, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2025 UNITY BIOTECHNOLOGY DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2025 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Co
July 22, 2025	EX-3.1	UNITY BIOTECHNOLOGY, INC. CERTIFICATE OF DESIGNATION SERIES A PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware EX-3.1 Exhibit 3.1 UNITY BIOTECHNOLOGY, INC. CERTIFICATE OF DESIGNATION OF SERIES A PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Unity Biotechnology, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by the board of directors of the Corporation (the “B
July 22, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2025 UNITY BIOTECHNOLOGY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2025 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commission
June 30, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 UNITY BIOTECHNOLOGY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commission
June 30, 2025	EX-2.1	PLAN OF COMPLETE LIQUIDATION AND DISSOLUTION OF UNITY BIOTECHNOLOGY, INC. Exhibit 2.1 PLAN OF COMPLETE LIQUIDATION AND DISSOLUTION OF UNITY BIOTECHNOLOGY, INC. This Plan of Complete Liquidation and Dissolution (the “Plan”) is intended to constitute a plan of distribution under Section 281(b) of the General Corporation Law of the State of Delaware (“DGCL”) and accomplish the complete liquidation and dissolution of Unity Biotechnology, Inc., a Delaware corporation (such c
June 20, 2025	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commission
May 5, 2025	EX-99.1	UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to afliber Exhibit 99.1 UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-to-treat DME patient population UBX1325 generally outperformed aflibercept in a pre-specified subgroup of
May 5, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2025 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commission F
April 22, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2025 UNITY BIOTECHNOLOG UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2025 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commissio
April 22, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38470 Unity Biotechnology, Inc.
April 22, 2025	EX-99.1	UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates Exhibit 99.1 UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) - UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2025. UNITY announce
April 11, 2025	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-3
April 4, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2025 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commission
March 24, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2025 UNITY BIOTECHNOLOG UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2025 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commissio
March 24, 2025	EX-99.2	Presentation of Unity Biotechnology, Inc., dated March 24, 2025 Exhibit 99.2
March 24, 2025	EX-99.1	UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was n Exhibit 99.1 UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% confidence interval), but did not meet statistical non-inferiority on the average of weeks 20
March 17, 2025	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2025 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commissio
March 10, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2025 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commission
March 10, 2025	EX-99.1	UNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.D., to the Board of Directors Exhibit 99.1 UNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.D., to the Board of Directors SAN FRANCISCO, Calif., March 10, 2025 – UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that Yehia Hashad, M.D., executive vice president of research and devel
March 7, 2025	EX-10.33	UNITY BIOTECHNOLOGY, INC. EMPLOYMENT AGREEMENT Exhibit 10.33 UNITY BIOTECHNOLOGY, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), entered into as of January 1, 2025 (the “Effective Date”), is made by and between Unity Biotechnology, Inc., a Delaware corporation (the “Company”) and Federico Grossi (“Executive” and, together with the Company, the “Parties”). This Agreement supersedes in its entirety that certain offer lett
March 7, 2025	EX-19.1	Insider Trading Policy Exhibit 19.1 UNITY BIOTECHNOLOGY, Inc. INSIDER TRADING compliance POLICY (Adopted March 13, 2018 – effective as of the company’s initial public offering) (Last updated: December 8, 2023) This Insider Trading Compliance Policy (this “Policy”) consists of seven sections: • Section I provides an overview; • Section II sets forth Unity Biotechnology, Inc.’s (the “Company”) policies prohibiting insider
March 7, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2025 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commission
March 7, 2025	S-8	As filed with the Securities and Exchange Commission on March 7, 2025 As filed with the Securities and Exchange Commission on March 7, 2025 Registration No.
March 7, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38470 Unity Biotechno
March 7, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Unity Biotechnology, Inc.
March 7, 2025	EX-99.1	UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates Exhibit 99.1 UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif., March 7, 2025 (GLOBE NEWSWIRE) - UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended D
January 6, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2025 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commissi
January 6, 2025	EX-99.1	UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer Exhibit 99.1 UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer SAN FRANCISCO, Calif., January 6, 2025 - UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today strengthened the executive leadership team with the appointment of Federico Grossi, M.D., Ph.D.,
November 14, 2024	SC 13G/A	UBX / Unity Biotechnology, Inc. / Alyeska Investment Group, L.P. Passive Investment SC 13G/A 1 alyeska-ubx093024a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Unity Biotechnology, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 91381U200 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the app
November 4, 2024	EX-99.1	UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates Exhibit 99.1 UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif., November 4, 2024 (GLOBE NEWSWIRE) - UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2024. “As rece
November 4, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38470 Unity Biotechnology, Inc.
November 4, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commiss
August 6, 2024	EX-99.1	UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates Exhibit 99.1 UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif., August 6, 2024 (GLOBE NEWSWIRE) - UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the second quarter ended June 30, 2024. “Having expan
August 6, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commissio
August 6, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38470 Unity Biotechnology, Inc.
June 21, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commission
May 14, 2024	EX-99.1	UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates Exhibit 99.1 UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) - UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2024. "Our team remain
May 14, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 UNITY BIOTECHNOLOGY, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commission
May 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38470 Unity Biotechnology, Inc.
April 26, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
April 26, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 15, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38470 Unity Biotechno
April 15, 2024	S-8	As filed with the Securities and Exchange Commission on April 15, 2024 As filed with the Securities and Exchange Commission on April 15, 2024 Registration No.
April 15, 2024	EX-10.41	Third Amended and Restated Non-Employee Director Compensation Program. Exhibit 10.41 UNITY BIOTECHNOLOGY, INC. THIRD AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (EFFECTIVE MARCH 26, 2024) The Unity Biotechnology, Inc. (the “Company”) Third Amended and Restated Non-Employee Director Compensation Program (the “Program”) was adopted under the Company’s 2018 Incentive Award Plan (the “Plan”) and became effective on March 26, 2024. Capitalized terms no
April 15, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Unity Biotechnology, Inc.
April 15, 2024	EX-99.1	UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates Exhibit 99.1 UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif., April 15, 2024 (GLOBE NEWSWIRE) - UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended
April 15, 2024	EX-97.1	Policy for Recovery of Erroneously Awarded Compensation Exhibit 97.1 UNITY BIOTECHNOLOGY, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION (Adopted September 14, 2023) (Effective as of October 1, 2023) UNITY Biotechnology, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 1, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise
April 15, 2024	EX-3.3	Amended and Restated Bylaws of Unity Biotechnology, Inc. Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF UNITY BIOTECHNOLOGY, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDURES
April 15, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commissio
April 2, 2024	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b‑25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b‑25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001‑38470 (Check One): ☒ Form 10‑K  Form 20‑F  Form 11‑K  Form 10‑Q  Form 10‑D  Form N‑CEN  Form N‑CSR For Period Ended: December 31, 2023 FORMCHECKBOX Transition Report on Form 10‑K FORMCHECKBOX Transition Report on Form 20‑F FORMCHECKBOX Transition Report on Form
March 20, 2024	8-K	Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commissio
February 14, 2024	SC 13G/A	US91381U2006 / UNITY Biotechnology Inc / Alyeska Investment Group, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
December 8, 2023	424B3	Unity Biotechnology, Inc. 2,271,580 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-275924 PROSPECTUS Unity Biotechnology, Inc. 2,271,580 Shares of Common Stock This prospectus relates to the resale by the selling stockholders named in this prospectus from time to time of up to 2,271,580 shares of our common stock, par value $0.0001 per share. These 2,271,580 shares of common stock consist of: • 2,143,000 sha
December 7, 2023	CORRESP	Unity Biotechnology, Inc. 285 East Grand Ave. South San Francisco, CA 94080 Unity Biotechnology, Inc. 285 East Grand Ave. South San Francisco, CA 94080 December 7, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission Washington, D.C. 20549 Attention: Joshua Gorsky Re: Unity Biotechnology, Inc. Registration Statement on Form S-3 Filed on December 6, 2023 File No. 333-275924 (the “R
December 6, 2023	S-3	As filed with the Securities and Exchange Commission on December 6, 2023 Table of Contents As filed with the Securities and Exchange Commission on December 6, 2023 Registration No.
December 6, 2023	EX-FILING FEES	Calculation of Filing Fee. Exhibit 107 Calculation of Filing Fee Tables Form S-3 Unity Biotechnology, Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forwa
November 13, 2023	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2023 UNITY BIOTECHNOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38470 26-4726035 (State or Other Jurisdiction of Incorporation) (Commis
November 13, 2023	EX-10.1	Inducement Offer to Exercise Common Stock Purchase Warrants Issued in November 9, 2023 Exhibit 10.1 UNITY BIOTECHNOLOGY, INC. November 9, 2023 Holder of Common Stock Purchase Warrants Issued in August 2022 Re: Inducement Offer to Exercise Common Stock Purchase Warrants Issued in August 2022 Dear Holder: UNITY Biotechnology, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) the opportunity to receive (i) new warrants to purchase shares of common
November 13, 2023	EX-4.1	Form of New Warrant. Exhibit 4.1 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXC
November 13, 2023	EX-99.1	UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates Exhibit 99.1 UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif., November 13, 2023 (GLOBE NEWSWIRE) - UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2023. “Follow
November 13, 2023	EX-99.1	UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds Exhibit 99.1 UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds SOUTH SAN FRANCISCO, Calif., November 10, 2023 – UNITY Biotechnology, Inc. (“UNITY” or the “Company”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced the entry into a definitive agreement for the immediate exercise of certai
November 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 UNITY BIOTECHNO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commis
November 13, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38470 Unity Biotechnology, Inc.
September 27, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2023 UNITY BIOTECHNOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38470 26-4726035 (State or Other Jurisdiction of Incorporation) (Commi
September 27, 2023	EX-99.1	UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration Patients on combination treatment with UBX1325 and aflibercept from weeks 24-48 maintained vision gains achieve Exhibit 99.1 UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration Patients on combination treatment with UBX1325 and aflibercept from weeks 24-48 maintained vision gains achieved at week 24 on aflibercept alone, with greater vision improvement in patients with more severe disease Patients with prior anti-VEGF tre
September 6, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 06, 2023 UNITY BIOTECHNOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38470 26-4726035 (State or Other Jurisdiction of Incorporation) (Commi
August 8, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commissio
August 8, 2023	EX-99.1	UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates Exhibit 99.1 UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif., August 8, 2023 (GLOBE NEWSWIRE) - UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the second quarter ended June 30, 2023. “We are focus
August 8, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38470 Unity Biotechnology, Inc.
June 23, 2023	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 UNITY BIOTECHNOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38470 26-4726035 (State or Other Jurisdiction of Incorporation) (Commission
May 9, 2023	EX-10	Second Amended and Restated Non-Employee Director Compensation Program (effective March 17, 2023). Exhibit Exhibit 10.3 Unity Biotechnology, Inc. Second Amended and Restated Non-Employee Director Compensation Program (Effective March 17, 2023) The Unity Biotechnology, Inc. (the “Company”) Second Amended and Restated Non-Employee Director Compensation Program (the “Program”) was adopted under the Company’s 2018 Incentive Award Plan (the “Plan”) and became effective on March 17, 2023. Capitalized
May 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 UNITY BIOTECHNOLOGY, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commission F
May 9, 2023	EX-99	UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business Updates Exhibit 99.1 UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif., May 9, 2023 (GLOBE NEWSWIRE) - UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2023. “The recent 48-we
May 9, 2023	EX-10	Separation Agreement, dated April 27, 2023, by and between Unity Biotechnology, Inc. and Jamie Dananberg. Exhibit 10.1 SEPARATION AGREEMENT This Separation Agreement (the “Agreement”) by and between Jamie Dananberg, M.D. (“Executive”), and Unity Biotechnology, Inc., a Delaware corporation (the “Company”), is made effective as of the eighth (8th) day following the date Executive signs this Agreement (the “Effective Date”) with reference to the following facts: A. Executive’s employment with the Company
May 9, 2023	EX-10	Amendment No. 2 to Loan and Security Agreement, dated January 25, 2023, by and between the Company and Hercules Capital, Inc. Exhibit 10.4 AMENDMENT NO. 2 TO LOAN AND SECURITY AGREEMENT This AMENDMENT NO. 2 (this “Amendment”) is entered into as of January 25, 2023 (the “Amendment Date”), by and between UNITY BIOTECHNOLOGY, INC., a Delaware corporation (“Borrower”) and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as a Lender (as defined below) and as administrative agent and collateral agent for the Len
May 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38470 Unity Biotechnology, Inc.
May 9, 2023	EX-10	Consulting Agreement, dated April 27, 2023, by and between Unity Biotechnology, Inc. and Jamie Dananberg. Exhibit 10.2 UNITY BIOTECHNOLOGY, INC. CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (“Agreement”) is entered into as of April 27, 2023 (the “Effective Date”) by and between UNITY BIOTECHNOLOGY, INC. (“UNITY”), and JAMIE DANANBERG (“Consultant”). UNITY desires to retain Consultant as an independent contractor to perform consulting services for UNITY, and Consultant is willing to perform such serv
April 28, 2023	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2023 UNITY BIOTECHNOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38470 26-4726035 (State or Other Jurisdiction of Incorporation) (Commiss
April 28, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A 1 ubx-2023def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as p
April 24, 2023	EX-99	UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema A single injection of UBX1325 led to a statistically significant and clinically meaningful improvement in Best Correct Exhibit 99.1 UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema A single injection of UBX1325 led to a statistically significant and clinically meaningful improvement in Best Corrected Visual Acuity (BCVA) of +6.2 ETDRS letters from baseline at 48 weeks Approximately 53% of UBX1325-treated patients did not require any
April 24, 2023	EX-99	Special Note Regarding Forward-Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements including statements related to Unity Biotechnology Inc.’s (“UNITY’s”) understanding of cellular senescence an NASDAQ: UBX UBX1325 Phase 2 BEHOLD Study in DME 48 Week Top Line Results Robert Bhisitkul, M.
April 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2023 UNITY BIOTECHNOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38470 26-4726035 (State or Other Jurisdiction of Incorporation) (Commissio
April 11, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2023 UNITY BIOTECHNOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38470 26-4726035 (State or Other Jurisdiction of Incorporation) (Commissio
March 27, 2023	EX-99	Special Note Regarding Forward-Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements including statements related to Unity Biotechnology Inc.’s (“UNITY’s”) understanding of cellular senescence an Arshad M. Khanani MD, MA, FASRS Director of Clinical Research at Sierra Eye Associates Anirvan Ghosh, CEO Jamie Dananberg, CMO Lynne Sullivan, CFO UBX1325 Phase 2 ENVISION nAMD Study 24 Week Data Exhibit 99.2 Special Note Regarding Forward-Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements including statements related to Unity Biotechnology
March 27, 2023	EX-99	UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration UBX1325 monotherapy did not achieve non-inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain in Exhibit 99.1 UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration UBX1325 monotherapy did not achieve non-inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain in the anti-VEGF control arm UBX1325 maintained visual acuity in patients with ongoing active disease through 24 weeks with less than one le
March 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 UNITY BIOTECHNOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38470 27-4726035 (State or Other Jurisdiction of Incorporation) (Commissio
March 17, 2023	EX-1.1	Amendment No. 2 to Sales Agreement, dated March 17, 2023, by and between Unity Biotechnology, Inc. and Cowen and Company LLC. Exhibit 1.1 AMENDMENT NO. 2 TO SALES AGREEMENT March 17, 2023 Unity Biotechnology, Inc. 285 East Grand Ave. South San Francisco, CA 94080 Ladies and Gentlemen: Unity Biotechnology, Inc., a Delaware corporation (the “Company”), and Cowen and Company, LLC (“Cowen”) are parties to that certain Sales Agreement dated March 15, 2022 (the “Original Agreement”), as amended by Amendment No. 1 thereto dated
March 17, 2023	424B5	$15,202,823 Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-263574 PROSPECTUS SUPPLEMENT (To prospectus dated May 6, 2022) $15,202,823 Common Stock We previously entered into a sales agreement with Cowen and Company, LLC, or Cowen, dated as of March 15, 2022, as amended on August 17, 2022 and March 17, 2023, or the “sales agreement,” relating to shares of our common stock offered
March 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2023 UNITY BIOTECHNOLOG UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2023 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commissio
March 15, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Unity Biotechnology, Inc.
March 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 UNITY BIOTECHNOLOG UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commissio
March 15, 2023	S-8	As filed with the Securities and Exchange Commission on March 15, 2023 As filed with the Securities and Exchange Commission on March 15, 2023 Registration No.
March 15, 2023	EX-99	Second Amendment to 2020 Employment Inducement Incentive Award Plan Exhibit 99.3(c) UNITY BIOTECHNOLOGY, INC. 2020 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN AMENDMENT #2 Pursuant to the authority reserved to the Board of Directors (the “Board”) of Unity Biotechnology, Inc., a Delaware corporation (the “Company”), under Section 11.4 of the Company’s 2020 Employment Inducement Incentive Award Plan (the “Plan”), the Board hereby amends the Plan as follows. 1. Sectio
March 15, 2023	10-K	Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38470 Unity Biotechno
March 15, 2023	EX-4	Description of Unity’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934. Exhibit 4.5 DESCRIPTION OF UNITY’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2022, Unity Biotechnology, Inc. had common stock, $0.0001 par value per share, registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and listed on The Nasdaq Global Select Market under the trading symbol “UBX.” Refe
March 15, 2023	EX-99	UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates Exhibit 99.1 UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif., March 15, 2023 (GLOBE NEWSWIRE) - UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended
March 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 UNITY BIOTECHNOLOG UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commissio
February 14, 2023	SC 13G	US91381U2006 / UNITY Biotechnology Inc / Alyeska Investment Group, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
November 8, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 08, 2022 UNITY BIOTECHNOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38470 27-4726035 (State or Other Jurisdiction of Incorporation) (Commis
November 8, 2022	EX-99.1	UNITY Biotechnology, Inc. Reports Third Quarter 2022 Financial Results and Business Updates - Announced positive 24-week data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema; single injection led to statistically significan Exhibit 99.1 UNITY Biotechnology, Inc. Reports Third Quarter 2022 Financial Results and Business Updates - Announced positive 24-week data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema; single injection led to statistically significant and clinically meaningful improvement in BCVA with favorable safety profile through six months - - 16-Week Data from Phase 2 ENVISION S
November 8, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38470 Unity Biotechnology, Inc.
November 8, 2022	EX-4.2	Form of Common Stock Certificate. Exhibit 4.2
November 1, 2022	EX-99.1	UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema A single injection of UBX1325 led to a statistically significant and clinically relevant improvement in Best Corrected Vi Exhibit 99.1 UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema A single injection of UBX1325 led to a statistically significant and clinically relevant improvement in Best Corrected Visual Acuity (BCVA) of 7.6 ETDRS letters at 24 weeks compared to sham treatment UBX1325 maintained stabilization of retinal structure, as
November 1, 2022	EX-99.2	Special Note Regarding Forward-Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements including statements related to Unity Biotechnology Inc.’s (“UNITY’s”) understanding of cellular senescence an Arshad M. Khanani MD, MA, FASRS Director of Clinical Research at Sierra Eye Associates Anirvan Ghosh, CEO Jamie Dananberg, CMO Lynne Sullivan, CFO UBX1325 Phase 2 BEHOLD DME Study 24 Week Data 01-Nov-2022 Exhibit 99.2 Special Note Regarding Forward-Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements including statements related to Unity Biot
November 1, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 01, 2022 UNITY BIOTECHNOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38470 27-4726035 (State or Other Jurisdiction of Incorporation) (Commis
October 26, 2022	424B5	$50,000,000 Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-267886 PROSPECTUS SUPPLEMENT (To prospectus dated October 24, 2022) $50,000,000 Common Stock We have entered into a sales agreement with Cowen and Company, LLC, or Cowen, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales
October 20, 2022	CORRESP	October 20, 2022 October 20, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Unity Biotechnology, Inc. Registration Statement on Form S-3 (File No. 333-267886) Request for Acceleration of Effective Date To the addressee set forth above: In accordance with Rule 461 under the Securities Act of 1933, as amende
October 19, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2022 UNITY BIOTECHNOL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2022 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commiss
October 19, 2022	EX-99.1	UNITY Biotechnology Announces Reverse Stock Split Effective at 5:00 PM Eastern Time Today UBX common stock expected to begin trading on a split-adjusted basis on October 20, 2022 Exhibit 99.1 UNITY Biotechnology Announces Reverse Stock Split Effective at 5:00 PM Eastern Time Today UBX common stock expected to begin trading on a split-adjusted basis on October 20, 2022 South San Francisco, Calif., October 19, 2022 (GLOBE NEWSWIRE) ? UNITY Biotechnology, Inc. (?UNITY? or the ?Company?) (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt or reverse dis
October 19, 2022	EX-3.1	Certificate of Amendment to Amended and Restated Certificate of Incorporation of Unity Biotechnology, Inc. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF UNITY BIOTECHNOLOGY, INC. Unity Biotechnology, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), DOES HEREBY CERTIFY: FIRST: The name of the Corporation is Unity Biotechnology, Inc. SECOND: The date on which the Certificate of Incorporation of the Corpo
October 14, 2022	EX-1.2	Sales Agreement, dated October 14, 2022, by and between Unity Biotechnology, Inc. and Cowen and Company, LLC. EX-1.2 2 d306843dex12.htm EX-1.2 Exhibit 1.2 UNITY BIOTECHNOLOGY, INC. $50,000,000 SHARES OF COMMON STOCK SALES AGREEMENT October 14, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Unity Biotechnology, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and
October 14, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) Unity Biotechnology, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration
October 14, 2022	EX-4.4	Form of Indenture. Exhibit 4.4 UNITY BIOTECHNOLOGY, INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Establ
October 14, 2022	S-3	Powers of Attorney (incorporated by reference to the signature page hereto). Table of Contents As filed with the Securities and Exchange Commission on October 14, 2022 Registration No.
September 13, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule
August 30, 2022	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule
August 22, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2022 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 27-4726035 (State or other jurisdiction of incorporation) (Commissi
August 22, 2022	EX-99.1	UNITY Biotechnology Announces Pricing of Upsized Underwritten Public Offering Exhibit 99.1 UNITY Biotechnology Announces Pricing of Upsized Underwritten Public Offering SOUTH SAN FRANCISCO, California, August 17, 2022 ? UNITY Biotechnology, Inc. (?UNITY?) (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced the pricing of an upsized underwritten public offering of 64,285,714 shares of its common stock and
August 22, 2022	EX-1.1	Underwriting Agreement, dated as of August 17, 2022, among Unity Biotechnology, Inc. and SVB Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives of the underwriters named therein. Exhibit 1.1 UNITY BIOTECHNOLOGY, INC. (a Delaware corporation) 64,285,714 Shares of Common Stock 64,285,714 Warrants to Purchase 64,285,714 Shares of Common Stock UNDERWRITING AGREEMENT August 17, 2022 SVB Securities LLC Cantor Fitzgerald & Co Mizuho Securities USA LLC as Representatives of the several Underwriters c/o SVB Securities LLC 53 State Street, 40th Floor Boston, MA 02109 c/o Cantor Fitz
August 22, 2022	EX-4.1	Form of Warrant. Exhibit 4.1 COMMON STOCK PURCHASE WARRANT Unity Biotechnology, Inc. Warrant number: CUSIP No.: 91381U 119 Warrant Shares: Issue Date: THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date her
August 19, 2022	424B5	64,285,714 Shares of Common Stock Warrants to Purchase 64,285,714 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-263574 Prospectus supplement (To prospectus dated May 6, 2022) 64,285,714 Shares of Common Stock Warrants to Purchase 64,285,714 Shares of Common Stock We are offering 64,285,714 shares of our common stock and accompanying common warrants to purchase up to 64,285,714 shares of our common stock, or the common warrants, pursuant
August 19, 2022	EX-1.1	Amendment No. 1 to Sales Agreement, dated August 17, 2022, by and between Unity Biotechnology, Inc. and Cowen and Company, LLC. EX-1.1 2 d379448dex11.htm EX-1.1 Exhibit 1.1 UNITY BIOTECHNOLOGY, INC. Shares of Common Stock ($0.0001 par value) AMENDMENT NO. 1 TO THE SALES AGREEMENT August 17, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Reference is made to the Sales Agreement, dated March 15, 2022 (the “Agreement”), by and between Unity Biotechnology, Inc., a Delaware corporation
August 19, 2022	424B5	$16,119,028 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-263574 PROSPECTUS SUPPLEMENT (To prospectus dated May 6, 2022) $16,119,028 Common Stock We previously entered into a sales agreement with Cowen and Company, LLC, or Cowen, dated as of March 15, 2022 and as amended on August 17, 2022, relating to shares of our common stock offered by this prospectus supplement and the accompany
August 19, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2022 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commissi
August 17, 2022	FWP	Issuer Free Writing Prospectus FWP 1 d372652dfwp.htm FWP Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated August 17, 2022 Relating to Preliminary Prospectus Dated August 16, 2022 Registration Statement No. 333-263574 $25,000,000 Shares of common stock Pre-funded warrants to purchase shares of common stock Warrants to purchase shares of common stock This free writing prospectus relates only to the offering describ
August 16, 2022	424B5	SUBJECT TO COMPLETION, PRELIMINARY PROSPECTUS SUPPLEMENT DATED AUGUST 16, 2022 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-263574 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but is not complete and may be changed. Neither this preliminary prospectus supplement nor the accompanying prospectus is an offer to sell these securities, and we are not soliciting an offer to buy th
August 12, 2022	EX-99.1	UNITY Biotechnology, Inc. Reports Second Quarter 2022 Financial Results and Business Updates - Announced Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema; single injection in subjects led to statistically signi Exhibit 99.1 UNITY Biotechnology, Inc. Reports Second Quarter 2022 Financial Results and Business Updates - Announced Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema; single injection in subjects led to statistically significant and clinically meaningful improvement in BCVA and CST with favorable safety profile at 12 and 18 weeks - - Near-Term Milestones in
August 12, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38470 Unity Biotechnology, Inc.
August 12, 2022	EX-99.2	UBX1325 Achieved Proof-of-Concept in Patients with Diabetic Macular Edema (DME) Built on UNITY’s Senescent Cell Biology Platform UBX1325, the first senolytic drug being explored in eye disease, had a favorable safety and tolerability profile, with no UBX1325 Phase 2 BEHOLD DME Study 12- and 18-Week Data August 12, 2022 Robert Bhisitkul, M.
August 12, 2022	EX-99.1	UNITY Biotechnology Announces Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema A single injection of UBX1325 led to a progressive, statistically significant, and clinically meaningful improvement in mean Best C Exhibit 99.1 UNITY Biotechnology Announces Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema A single injection of UBX1325 led to a progressive, statistically significant, and clinically meaningful improvement in mean Best Corrected Visual Acuity (BCVA) at 12- and 18-weeks compared to sham treatment UBX1325 treatment also stabilized retinal structure, as meas
August 12, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2022 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commissi
August 12, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2022 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commissi
July 5, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2022 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commission
June 27, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2022 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commission
June 7, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2022 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commission
May 26, 2022	EX-99.1	UNITY Biotechnology Announces Appointment of Accomplished Finance and Operations Executive Michael Samar to the Board of Directors Exhibit 99.1 UNITY Biotechnology Announces Appointment of Accomplished Finance and Operations Executive Michael Samar to the Board of Directors SAN FRANCISCO, Calif., May 26, 2022 ? UNITY Biotechnology, Inc. (?UNITY?) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that Michael Samar, current chief financial officer at Ass
May 26, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2022 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commission
May 13, 2022	424B5	$50,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-263574 PROSPECTUS SUPPLEMENT (To prospectus dated May 6, 2022) $50,000,000 Common Stock We have entered into a sales agreement with Cowen and Company, LLC, or Cowen, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreement,
May 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38470 Unity Biotechnology, Inc.
May 10, 2022	EX-99.1	UNITY Biotechnology, Inc. Reports First Quarter 2022 Financial Results and Business Updates -Completed enrollment in BEHOLD, the Phase 2 clinical trial of UBX1325 in DME; BEHOLD remains on track with 12-week safety and efficacy data anticipated by mi Exhibit 99.1 UNITY Biotechnology, Inc. Reports First Quarter 2022 Financial Results and Business Updates -Completed enrollment in BEHOLD, the Phase 2 clinical trial of UBX1325 in DME; BEHOLD remains on track with 12-week safety and efficacy data anticipated by mid-year 2022- -Dosed first patient in ENVISION, the Phase 2 clinical trial of UBX1325 in wet age-related macular degeneration; ENVISION re
May 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commission
May 4, 2022	CORRESP	May 4, 2022 May 4, 2022 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
April 29, 2022	DEF 14A	Schedule 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 29, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 12, 2022	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 1, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commissio
March 15, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Unity Biotechnology, Inc.
March 15, 2022	S-3	As filed with the Securities and Exchange Commission on March 15, 2022 As filed with the Securities and Exchange Commission on March 15, 2022 Registration No.
March 15, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Unity Biotechnology, Inc.
March 15, 2022	EX-99.1	UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates Exhibit 99.1 UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) - UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended
March 15, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38470 Unity Biotechno
March 15, 2022	EX-1.2	Sales Agreement, dated March 15, 2022, by and between Unity Biotechnology, Inc. and Cowen and Company , LLC. Exhibit 1.2 unity biotechnology, inc. $50,000,000 shares of common stock SALES AGREEMENT March 15, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Unity Biotechnology, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees
March 15, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commissio
March 15, 2022	S-8	As filed with the Securities and Exchange Commission on March 15, 2022 As filed with the Securities and Exchange Commission on March 15, 2022 Registration No.
February 14, 2022	SC 13G/A	UBX / Unity Biotechnology Inc / Venrock Associates Vii, L.p. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Unity Biotechnology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 91381U 10 1 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
February 11, 2022	SC 13G/A	UBX / Unity Biotechnology Inc / ARCH Venture Fund VII, L.P. - ARCH VENTURE FUND VII, L.P. - UNITY BIOTECHNOLOGY -- SCH 13G/A (#3) Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Unity Biotechnology, Inc. (Name of Issuer) Common Stock par value $0.0001 per share (Title of Class of Securities) 91381U101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate t
February 3, 2022	EX-99.1	UNITY Biotechnology Announces Restructuring to Advance Corporate Strategy and Focus on Key Ophthalmology Programs Strategic realignment to focus capital resources on clinical programs and extend cash runway into Q1 2023 12-week data from Phase 2a stu Exhibit 99.1 UNITY Biotechnology Announces Restructuring to Advance Corporate Strategy and Focus on Key Ophthalmology Programs Strategic realignment to focus capital resources on clinical programs and extend cash runway into Q1 2023 12-week data from Phase 2a study of UBX1325 in diabetic macular edema (DME) expected mid-2022 16-week data from Phase 2 study in wet age-related macular degeneration (
February 3, 2022	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2022 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commiss
December 20, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2021 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commis
December 20, 2021	EX-10.1	Press release titled “UNITY Biotechnology Announces Exclusive License Agreement with Jocasta Neuroscience to Continue Development of α-Klotho Program” Exhibit 99.1 UNITY Biotechnology Announces Exclusive License Agreement with Jocasta Neuroscience to Continue Development of ?-Klotho Program SOUTH SAN FRANCISCO, Calif., December 20, 2021 ? UNITY Biotechnology, Inc. (?UNITY?) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced it has signed an exclusive agreement licensing its
December 15, 2021	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2021 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commis
December 15, 2021	EX-10.1	Amendment No. 1 to Loan and Security Agreement, dated December 15, 2021, by and between the Company and Hercules Capital, Inc. Exhibit 10.1 AMENDMENT NO. 1 TO LOAN AND SECURITY AGREEMENT This AMENDMENT NO. 1 (this ?Amendment?) is entered into as of December 15, 2021 (the ?Amendment Date?), by and between Unity Biotechnology, Inc., a Delaware corporation (?Borrower?) and Hercules Capital, Inc., a Maryland corporation, in its capacity as a Lender (as defined below) and as administrative agent and collateral agent for the Le
November 10, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38470 Unity Biotechnology, Inc.
November 10, 2021	EX-99.1	UNITY Biotechnology, Inc. Reports Third Quarter 2021 Financial Results and Business Updates Exhibit 99.1 UNITY Biotechnology, Inc. Reports Third Quarter 2021 Financial Results and Business Updates - UBX1325 Phase 2 study in DME currently enrolling, with additional Phase 2 study in AMD planned for 1H22 - UNITY to present at invitation-only Eyecelerator innovation conference at AAO SOUTH SAN FRANCISCO, Calif., November 10, 2021 (GLOBE NEWSWIRE) - UNITY Biotechnology, Inc. (UNITY) [NASDAQ:U
November 10, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commis
October 4, 2021	144	OMB APPROVAL OMB APPROVAL OMB Number: 3235-0101 Expires: July 31, 2023 Estimated average burden hours per response.
September 29, 2021	424B5	Up to $30,000,000 of shares of Common Stock and 252,447 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-231893 Prospectus supplement (To prospectus dated June 6, 2019) Up to $30,000,000 of shares of Common Stock and 252,447 Shares of Common Stock This prospectus supplement relates to the issuance and sale of up to $30,000,000 of shares of our common stock, or Purchase Shares, that we may sell to Lincoln Park Capital Fund, LLC, o
September 29, 2021	EX-10.2	Registration Rights Agreement, dated September 29, 2021, by and between Unity Biotechnology and Lincoln Park Capital Fund, LLC. Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of September 29, 2021, is entered into by and between UNITY BIOTECHNOLOGY, INC., a Delaware corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the ?Investor?). Capitalized terms used herein and not other
September 29, 2021	EX-10.1	Purchase Agreement, dated as of September 29, 2021, by and between the Registrant and Lincoln Park Capital Fund, LLC Exhibit 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the ?Agreement?), dated as of September 29, 2021, is made by and between UNITY BIOTECHNOLOGY, INC., a Delaware corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the ?Investor?). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Inv
September 29, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2021 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commi
August 10, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commissi
August 10, 2021	EX-99.1	UNITY Biotechnology, Inc. Reports Second Quarter 2021 Financial Results and Business Updates Exhibit 99.1 UNITY Biotechnology, Inc. Reports Second Quarter 2021 Financial Results and Business Updates - UBX1325 demonstrates favorable tolerability in Phase 1 safety study and improvement in visual acuity and central subfield thickness in majority of patients with diabetic macular edema (DME) and wet age-related macular degeneration (AMD) - Results from Phase 1 study of UBX1325 in additional p
August 10, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38470 Unity Biotechnology, Inc.
July 7, 2021	8-K/A	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2021 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commissio
July 7, 2021	EX-99.2	SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 2 This presentation and the accompanying oral commentary contain forward-looking statements including statements related to UNITY’s understanding of cellular senescence and the role it plays in diseas EX-99.2 2 ubx-ex99210.htm EX-99.2 1 UBX1325 Phase 1 Data Conference Call July 6th, 2021 Anirvan Ghosh, CEO Jamie Dananberg, CMO Lynne Sullivan, CFO Exhibit 99.2 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 2 This presentation and the accompanying oral commentary contain forward-looking statements including statements related to UNITY’s understanding of cellular senescence and the role it play
July 6, 2021	EX-99.2	SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 2 This presentation and the accompanying oral commentary contain forward-looking statements including statements related to UNITY’s understanding of cellular senescence and the role it plays in diseas 1 UBX1325 Phase 1 Data Conference Call July 6th, 2021 Anirvan Ghosh, CEO Jamie Dananberg, CMO Lynne Sullivan, CFO Exhibit 99.
July 6, 2021	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2021 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commission
July 6, 2021	EX-99.1	UNITY Biotechnology Announces Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease Improvement in Visual Acuity and Central Subfield Thickness observed in diabetic macular edema (DME) and wet age-related Exhibit 99.1 UNITY Biotechnology Announces Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease Improvement in Visual Acuity and Central Subfield Thickness observed in diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD) patients treated with UBX1325 UBX1325 advances to Phase 2a study in DME patients as a potential alternati
June 24, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2021 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commission
May 11, 2021	EX-10.1	Employment Agreement, dated March 8, 2021, by and between Unity Biotechnology, Inc. and Alexander Nguyen Exhibit 10.1 UNITY BIOTECHNOLOGY, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), entered into as of March 8, 2021 (the ?Effective Date?), is made by and between Unity Biotechnology, Inc., a Delaware corporation (the ?Company?) and Alexander Nguyen (?Executive? and, together with the Company, the ?Parties?). This Agreement supersedes in its entirety that certain offer letter
May 11, 2021	EX-99.1	UNITY Biotechnology, Inc. Reports First Quarter 2021 Financial Results and Business Updates - UBX1325 demonstrates favorable tolerability in Phase 1 safety study with initial evidence of relevant biological activity - Phase 2a proof-of-concept study Exhibit 99.1 UNITY Biotechnology, Inc. Reports First Quarter 2021 Financial Results and Business Updates - UBX1325 demonstrates favorable tolerability in Phase 1 safety study with initial evidence of relevant biological activity - Phase 2a proof-of-concept study initiated in patients with diabetic macular edema; data expected first half of 2022 - Cash balance sufficient to fund operations into sec
May 11, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2021 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commission
May 11, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38470 Unity Biotechnology, Inc.
April 30, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ????Filed by a party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy
April 30, 2021	DEF 14A	- DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? ? ? ? ? Filed by a party other than the Registrant ? ? ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitted by R
March 23, 2021	EX-10.19A	Exclusive License Agreement, dated as of June 28, 2013, by and between the Mayo Foundation for Medical Education and Research and Unity Biotechnology, Inc. Exhibit 10.19A EXCLUSIVE LICENSE AGREEMENT This License Agreement ("Agreement") is made as is made as of the 28th day of June, 2013 (the "Effective Date") by and between the Mayo Foundation for Medical Education and Research, having its principal place of business at 200 First Street SW, Rochester, MN 55905("Mayo"), and Cenexys, Inc., a Delaware corporation, having a place of business at 1700 Owen
March 23, 2021	EX-10.19B	Amendment No. 1 to Exclusive License Agreement, dated as of September 10, 2014, by and between the Mayo Foundation for Medical Education and Research and Unity Biotechnology, Inc. Exhibit 10.19B AMENDMENT NO. 1 TO EXCLUSIVE LICENSE AGREEMENT THIS Amendment No.1 to Exclusive License Agreement ("Amendment") is made and entered hinto this 10th day of September 2014 ("Effective Date"), by and between the Mayo Foundation for Medical Education and Research ("Mayo") having its principal place of business at 200 First Street SW, Rochester, MN 55905, and Cenexys, Inc., a Delaware co
March 23, 2021	EX-10.15	APG1252 License Agreement, dated as of February 2, 2016, by and between Ascentage Pharma Group Corp. Ltd. and Unity Biotechnology, Inc. Exhibit 10.15 APG1252 License Agreement This APG1252 License Agreement (the ?Agreement?) effective as of the 2nd day of Feburary, 2016, (the ?Signing Date?) is made by and between Ascentage Pharma Group Corp. Ltd., a Hong Kong corporation (?Ascentage?), with a business address at 11/F, AXA CENTRE, Gloucester Road, Wanchai, Hong Kong, and Unity Biotechnology, Inc., a Delaware corporation (?Unity?),
March 23, 2021	EX-10.19F	Addendum to Amendment No. 4 to Exclusive License Agreement, dated as of September 15, 2016, by and between the Mayo Foundation for Medical Education and Research and Unity Biotechnology, Inc. Exhibit 10.19F Unity Biotechnology 3280 Bayshore Blvd., Suite 100 Brisbane, CA 94005 September 15, 2016 Mayo Foundation for Medical Education and Research 200 First Street SW Rochester, MN 55905 Attn: Daniel D. Estes re:Addendum to Amendment 4 to Exclusive License Agreement Dear Daniel: As you know, Mayo Foundation for Medical Education and Research ("Mayo") and Unity Biotechnology, Inc. ("Unity")
March 23, 2021	EX-10.17	Amendment to APG1252 License Agreement, dated as of February 2, 2016, by and between Ascentage Pharma Group Corp. Ltd. Exhibit 10.17 FIRST AMENDMENT TO APG1252 LICENSE AGREEMENT This Amendment (the ?Amendment?), dated as of March 28, 2018 (the Amendment Effective Date?) is made by and between Ascentage Pharma Group Corp. Ltd., a Hong Kong corporation (?Ascentage?), with a business address at 11/F, AXA CENTRE, Gloucester Road, Wanchai, Hong Kong, and Unity Biotechnology, Inc., a Delaware corporation (?Unity?), with
March 23, 2021	EX-10.21	License Agreement, dated as of November 3, 2016, by and between The Johns Hopkins University and Unity Biotechnology, Inc. Exhibit 10.21 EXCLUSIVE LICENSE AGREEMENT BETWEEN THE JOHNS HOPKINS UNIVERSITY & UNITY BIOTECHNOLOGY, INC. JHU Agreement: A30652 ***Certain information contained herein has been omitted pursuant to Regulation S-K 601(b)(10). Confidential treatment has been granted with respect to the omitted portions. LICENSE AGREEMENT THIS LICENSE AGREEMENT (the ?Agreement?) is entered into by and between THE JOH
March 23, 2021	EX-99.1	UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Business Updates Exhibit 99.1 UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif., March 23, 2021 (GLOBE NEWSWIRE) - UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended
March 23, 2021	EX-10.19D	Amendment No. 3 to Exclusive License Agreement, dated as of May 5, 2015, by and between the Mayo Foundation for Medical Education and Research and Unity Biotechnology, Inc. Exhibit 10.19D AMENDMENT NO. 3 TO EXCLUSIVE LICENSE AGREEMENT THIS Amendment No. 3 to Exclusive License Agreement ("Amendment 3") is made and entered into this 5th day of May, 2015 ("Effective Date of Amendment 3"), by and between the Mayo Foundation for Medical Education and Research ("Mayo") having its principal place of business at 200 First Street SW, Rochester, Minnesota 55905, and Unity Biot
March 23, 2021	EX-10.14	Compound Library and Option Agreement, dated as of February 2, 2016, by and between Ascentage Pharma Group Corp. Ltd. and Unity Biotechnology, Inc. Exhibit 10.14 COMPOUND LIBRARY AND OPTION AGREEMENT This Compound Library and Option Agreement (the ?Agreement?), dated as of February 2nd, 2016 (the ?Signing Date?), is made by and between Ascentage Pharma Group Corp. Ltd., a Hong Kong corporation (?Ascentage?), with a business address at 11/F, AXA CENTRE, Gloucester Road, Wanchai, Hong Kong, and Unity Biotechnology, Inc., a Delaware corporation
March 23, 2021	EX-10.20	Amended and Restated License Agreement, dated as of January 27, 2017, by and between the Buck Institute for Research on Aging and Unity Biotechnology, Inc. Exhibit 10.20 AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT This Amended and Restated License Agreement (?Agreement?) is made as of the 27th day of January, 2017 (the ?Signature Date?) by and between the Buck Institute for Research on Aging, a California non-profit public benefit corporation having its principal place of business at 8001 Redwood Boulevard, Novato, California 94945 (?Buck?), and
March 23, 2021	EX-10.19G	Amendment No. 5 to Exclusive License Agreement, dated as of October 17, 2016, by and between the Mayo Foundation for Medical Education and Research and Unity Biotechnology, Inc. Exhibit 10.19G AMENDMENT NO. 5 TO EXCLUSIVE LICENSE AGREEMENT THIS Amendment No.5 to Exclusive License Agreement (?Amendment 5?) is made and entered into this 12th day of October, 2016 (?Effective Date of Amendment 5?), by and between the Mayo Foundation for Medical Education and Research (?Mayo?) having its principal place of business at 200 First Street SW, Rochester, MN 55905, and Unity Biotech
March 23, 2021	S-8	- S-8 S-8 1 ubx-s8.htm S-8 As filed with the Securities and Exchange Commission on March 23, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Unity Biotechnology, Inc. (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organizati
March 23, 2021	EX-10.18	Amendment to Compound Library and Option Agreement, dated as of February 2, 2016, by and between Ascentage Pharma Group Corp. Ltd. and Unity Biotechnology, Inc. Exhibit 10.18 FIRST AMENDMENT TO COMPOUND LIBRARY AND OPTION AGREEMENT This Amendment (the ?Amendment?), dated as of March 28, 2018 (the Amendment Effective Date?) is made by and between Ascentage Pharma Group Corp. Ltd., a Hong Kong corporation (?Ascentage?), with a business address at 11/F, AXA CENTRE, Gloucester Road, Wanchai, Hong Kong, and Unity Biotechnology, Inc., a Delaware corporation (?U
March 23, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2021 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commissio
March 23, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38470 Unity Biotechno
March 23, 2021	EX-10.38	Transition and Separation Agreement, dated December 12, 2020, by and between Nathaniel David and Unity Biotechnology, Inc. Exhibit 10.38 TRANSITION AND SEPARATION AGREEMENT This Transition and Separation Agreement (the ?Agreement?) by and between Nathaniel David (?Executive?) and Unity Biotechnology, Inc., a Delaware corporation (the ?Company?), is made effective as of the date Executive signs this Agreement (the ?Effective Date?) with reference to the following facts: A.Executive?s employment with the Company and eac
March 23, 2021	EX-10.19E	Amendment No. 4 to Exclusive License Agreement, dated as of September 15, 2016, by and between the Mayo Foundation for Medical Education and Research and Unity Biotechnology, Inc. Exhibit 10.19E AMENDMENT NO. 4 TO EXCLUSIVE LICENSE AGREEMENT THIS Amendment No. 4 to Exclusive License Agreement ("Amendment No. 4") is made and entered into this 15th day of September 2016 ("Effective Date of Amendment No. 4"), by and between the Mayo Foundation for Medical Education and Research ("Mayo") having its principal place of business at 200 First Street SW, Rochester, Minnesota 55905,
February 2, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Unity Biotechnology, Inc. (Name of Issuer) Common Stock par value $0.0001 per share (Title of Class of S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Unity Biotechnology, Inc. (Name of Issuer) Common Stock par value $0.0001 per share (Title of Class of Securities) 91381U101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate t
January 8, 2021	SC 13G	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Unity Biotechnology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 913 SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Unity Biotechnology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 91381U 101 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul
January 8, 2021	EX-99.1	Joint Filing Agreement by WuXi PharmaTech Healthcare Fund I L.P. and WuXi AppTec Co., Ltd., dated as of January 7, 2021 (incorporate by reference to Exhibit 99.1 from Schedule 13G filed by the Reporting Persons on January 8, 2021). EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT This joint filing agreement (this “Agreement”) is made and entered into as of January 7, 2021 by WuXi PharmaTech Healthcare Fund I L.P. and WuXi AppTec Co., Ltd. The parties to this Agreement agree to prepare jointly and file timely (and otherwise to deliver as appropriate) all filings on any Form 3, Form 4, Form 5, Schedule 13D or Schedule 13G, and any
December 14, 2020	EX-99.1	UNITY Biotechnology Announces Appointment of Clinical Development and Industry Veteran Gilmore O’Neill, M.B., to the Board of Directors Nathaniel E. David, Ph.D., to step down from Management Team, but will remain on UNITY’s Board Changes Reflect Str EX-99.1 Exhibit 99.1 UNITY Biotechnology Announces Appointment of Clinical Development and Industry Veteran Gilmore O’Neill, M.B., to the Board of Directors Nathaniel E. David, Ph.D., to step down from Management Team, but will remain on UNITY’s Board Changes Reflect Strategic Focus on Clinical Development in Age-Related Diseases of the Eye and Brain SOUTH SAN FRANCISCO, Calif., December 14, 2020
December 14, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2020 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commiss
November 24, 2020	EX-99.1(B)	Amendment to 2020 Employment Inducement Incentive Award Plan Exhibit 99.1(b) UNITY BIOTECHNOLOGY, INC. 2020 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN AMENDMENT Pursuant to the authority reserved to the Board of Directors (the “Board”) of Unity Biotechnology, Inc., a Delaware corporation (the “Company”), under Section 11.4 of the Company’s 2020 Employment Inducement Incentive Award Plan (the “Plan”), the Board hereby amends the Plan as follows. 1. Section 2
November 24, 2020	S-8	- S-8 As filed with the Securities and Exchange Commission on November 24, 2020 Registration No.
November 4, 2020	EX-99.1	UNITY Biotechnology, Inc. Reports Third Quarter 2020 Financial Results and Clinical Program Updates Exhibit 99.1 UNITY Biotechnology, Inc. Reports Third Quarter 2020 Financial Results and Clinical Program Updates SOUTH SAN FRANCISCO, Calif., November 4, 2020 (GLOBE NEWSWIRE) - UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2020. “
November 4, 2020	EX-10.2	Employment Agreement, dated August 1, 2020, by and between Unity Biotechnology, Inc. and Lynne Sullivan. Exhibit 10.2 UNITY BIOTECHNOLOGY, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), entered into as of August 1, 2020 (the “Effective Date”), is made by and between Unity Biotechnology, Inc., a Delaware corporation (the “Company”) and Lynne Sullivan (“Executive” and, together with the Company, the “Parties”). This Agreement supersedes in its entirety that certain offer letter
November 4, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2020 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commiss
November 4, 2020	EX-10.3	Amendment to Employment Agreement, dated September 1, 2020, by and between Unity Biotechnology, Inc. and Lynne Sullivan. Exhibit 10.3 UNITY BIOTECHNOLOGY, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”), entered into as of September 1, 2020 (the “Effective Date”), is made by and between Unity Biotechnology, Inc., a Delaware corporation (the “Company”) and Lynne Sullivan (“Executive” and, together with the Company, the “Parties”) and amends and restates
November 4, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38470 Unity Biotechnology, Inc.
September 24, 2020	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2020 UNITY BIOTECHN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2020 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commi
September 16, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2020 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commi
September 16, 2020	EX-99.1	UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology - Corporate restructuring to extend cash runway through mid-2022 and key milestones - - UBX1325 to enter clinical development in patients with diabeti EX-99.1 Exhibit 99.1 UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology - Corporate restructuring to extend cash runway through mid-2022 and key milestones - - UBX1325 to enter clinical development in patients with diabetic macular edema - SAN FRANCISCO, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) - UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechn
August 31, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2020 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commissi
August 17, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2020 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commissi
August 17, 2020	EX-99.1	UNITY Biotechnology Announces 12-week data from UBX0101 Phase 2 Clinical Study in Patients with Painful Osteoarthritis of the Knee EX-99.1 Exhibit 99.1 UNITY Biotechnology Announces 12-week data from UBX0101 Phase 2 Clinical Study in Patients with Painful Osteoarthritis of the Knee • UBX0101 failed to meet 12-week primary endpoint • Guidance for UNITY’s Bcl-xL inhibitor UBX1325 in retinal disease remains unchanged • UNITY to focus senescence programs on ophthalmologic and neurologic diseases in near- to mid-term • UNITY to ho
August 4, 2020	EX-10.1	Loan and Security Agreement, dated August 3, 2020, between Unity Biotechnology, Inc. and Hercules Capital. Inc. EX-10.1 Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of August 3, 2020 and is entered into by and among UNITY BIOTECHNOLOGY, INC., a Delaware corporation, each of its Subsidiaries from time to time party hereto as borrower (individually or collectively, as the context may require, “Borrower”), and the several banks and other financial institutions
August 4, 2020	EX-99.1	UNITY BIOTECHNOLOGY ANNOUNCES $80M DEBT FINANCING FROM HERCULES CAPITAL EX-99.1 Exhibit 99.1 UNITY BIOTECHNOLOGY ANNOUNCES $80M DEBT FINANCING FROM HERCULES CAPITAL SAN FRANCISCO, Calif., August 4, 2020 — UNITY Biotechnology (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that it has entered into a $80 million debt facility with Hercules Capital [NYSE: HTGC].
August 4, 2020	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2020 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commissio
July 31, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2020 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commission
July 31, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38470 Unity Biotechnology, Inc.
July 31, 2020	424B5	$50,000,000 Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-231893 PROSPECTUS SUPPLEMENT (To prospectus dated June 6, 2019) $50,000,000 Common Stock We have entered into a sales agreement with Cowen and Company, LLC, or Cowen, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agr
July 31, 2020	EX-99.1	UNITY Biotechnology, Inc. Reports Second Quarter 2020 Financial Results and Clinical Program Updates Exhibit 99.1 UNITY Biotechnology, Inc. Reports Second Quarter 2020 Financial Results and Clinical Program Updates SOUTH SAN FRANCISCO, Calif., July 31, 2020 (GLOBE NEWSWIRE) - UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported financial results for the second quarter
July 31, 2020	EX-1.1	Sales Agreement, dated July 31, 2020, by and between Unity Biotechnology, Inc. and Cowen and Company, LLC. Exhibit 1.1 unity biotechnology, inc. $50,000,000 shares of common stock SALES AGREEMENT July 31, 2020 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Unity Biotechnology, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees t
July 31, 2020	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2020 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of
July 6, 2020	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2020 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commission
July 1, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2020 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commission
July 1, 2020	EX-10.1	Third Amendment to Compound License Agreement for APG-1197, dated June 29, 2020, by and between Ascentage Pharma Group Corp. Ltd. and Unity Biotechnology, Inc. Exhibit 10.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. THIRD AMENDMENT TO COMPOUND LICENSE AGREEMENT FOR APG-1197 This third amendment (the “Third Amendment”) to the Compound License Agreement for APG1197 dated Ja
June 24, 2020	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2020 UNITY BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-38470 26-4726035 (State or other jurisdiction of incorporation) (Commission

UBX / Unity Biotechnology, Inc. - Depositi SEC, Relazione annuale, dichiarazione di delega

Statistiche di base

SEC Filings

SEC Filings (Chronological Order)

Other Listings